 - Arm II: Patients receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone LHRH agonist leuprolide, goserelin, buserelin, or triptorelin subcutaneously or as an injection every 1 to 3 months AND an oral antiandrogen therapy flutamide 3 times daily or bicalutamide once daily for 6 months. Beginning 8 weeks after the first LHRH injection, patients undergo radiotherapy as in arm I. 